vibegron: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
vibegron: clinical details
Prescribing considerations
- Assess for impaired bladder emptying or bladder outlet obstruction.
- Safety and efficacy have not been established in people under 18 years.
- Not recommended in end-stage renal disease or severe hepatic impairment because these populations have not been studied.
Contraindications and cautions
- Hypersensitivity to vibegron or any excipient.
- The formulation should not be used in patients with galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
Monitoring
- Assess for urinary retention, particularly with bladder outlet obstruction or concurrent antimuscarinic use.
- Discontinue and assess if urinary retention develops.
- Monitor serum digoxin concentrations when combined with digoxin.
Clinical pharmacology
Vibegron is a selective beta-3 adrenergic receptor agonist that relaxes detrusor smooth muscle during bladder filling.
Formulation and product differences
- The selected product is a lactose-containing film-coated tablet that may be swallowed whole or crushed and mixed with soft food for immediate administration.
- The tablet is essentially sodium-free.
vibegron preparations and strengths
Tablet
Route: Oral
Strengths: 75 mg
vibegron interactions
Tell the prescriber or pharmacist about all medicines being used, particularly the following.
Digoxin
Vibegron can increase digoxin exposure, so blood concentrations should be monitored and treatment adjusted where necessary.
Dabigatran etexilate, apixaban or rivaroxaban
These are sensitive P-glycoprotein substrates with a narrow safety margin; the potential interaction should be considered clinically.
Antimuscarinic bladder medicines
Combined treatment may increase the risk of urinary retention, especially where bladder outlet obstruction is present.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.